Cns Pharmaceuticals Inc (NASDAQ: CNSP)’s stock price has plunge by 10.43%relation to previous closing price of $0.85. Nevertheless, the company has seen a 17.49% surge in its stock price over the last five trading sessions. accessnewswire.com reported 2025-06-24 that Moderated discussion with founding physician of the Brain Tumor Center and Director of Neuro-Oncology at Piedmont Atlanta Hospital, Dr. Erin Dunbar HOUSTON, TX / ACCESS Newswire / June 24, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced the release of a Virtual Investor KOL Connect segment featuring Dr. Erin Dunbar, a founding physician of the Brain Tumor Center and Director of Neuro-Oncology at Piedmont Atlanta Hospital, who specializes in the comprehensive care of brain and spine tumor patients who are battling both primary and metastatic tumors. As part of the segment, Dr. Dunbar discussed the patient journey and current treatment landscape for Glioblastoma Multiforme and CNS Pharma’s lead product candidate, TPI 287, and its potential as a treatment for GBM as well as for future indications in metastatic tumors.
Is It Worth Investing in Cns Pharmaceuticals Inc (NASDAQ: CNSP) Right Now?
CNSP has 36-month beta value of 0.75. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for CNSP is 5.42M, and currently, short sellers hold a 8.51% ratio of that float. The average trading volume of CNSP on July 03, 2025 was 1.71M shares.
CNSP’s Market Performance
CNSP’s stock has seen a 17.49% increase for the week, with a -6.01% drop in the past month and a -27.14% fall in the past quarter. The volatility ratio for the week is 12.98%, and the volatility levels for the past 30 days are at 9.51% for Cns Pharmaceuticals Inc The simple moving average for the past 20 days is 6.57% for CNSP’s stock, with a -75.82% simple moving average for the past 200 days.
Analysts’ Opinion of CNSP
Ladenburg Thalmann, on the other hand, stated in their research note that they expect to see CNSP reach a price target of $11. The rating they have provided for CNSP stocks is “Buy” according to the report published on August 24th, 2020.
CNSP Trading at -8.03% from the 50-Day Moving Average
After a stumble in the market that brought CNSP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.36% of loss for the given period.
Stock Fundamentals for CNSP
Current profitability levels for the company are sitting at:
- -4998.33 for the present operating margin
- 0.02 for the gross margin
The net margin for Cns Pharmaceuticals Inc stands at -4972.73. The total capital return value is set at -1.43. Equity return is now at value -477.53, with -202.65 for asset returns.
Based on Cns Pharmaceuticals Inc (CNSP), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -81.47. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -4774.79.
Currently, EBITDA for the company is -14.9 million with net debt to EBITDA at 0.82. When we switch over and look at the enterprise to sales, we see a ratio of -2453.26. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.93.
Conclusion
To put it simply, Cns Pharmaceuticals Inc (CNSP) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
